UNSPSC 51203700: Immunosupressant heavy metals

This classification denotes substances that consist in whole or material part of arsenic, cadmium, chromium, lead, and/or mercury, substances called heavy metals, that reduce a human host's humoral and/or cell-mediated defense mechanisms against deviant native cells, foreign organisms, or foreign substances (the human immune response and system thereof), thus the term IMMUNOSUPPRESSANT HEAVY METALS.

UNSPSC 51203700 Immunosuppressant heavy metals is a Class code that does not align with the recent state and local procurement activity tagged under it. The code nominally encompasses chemical compounds used in medical immunosuppression, but the four recent opportunities posted between January and June 2026 solicit naloxone and drug deactivation systems, medical and first aid supplies for emergency response, direct-to-manufacturer prescription programs, and generic pharmaceuticals and over-the-counter products — none of which match the code's stated scope. The issuing bodies span a health department (Texas Health and Human Services Commission), a municipal fire department procurement (City of Tampa), a county health function (Seminole County, Florida), and a multi-state cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities in Minnesota and Oregon). The mismatch between the code's name and the actual procurements suggests either a systematic tagging error or that the code is being applied to a much broader set of health-related goods and services than its name indicates.

The geographic spread includes Texas, Florida, Minnesota, and Oregon, with activity concentrated in the Southeast and Upper Midwest. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, though posted June 30, 2026); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division (estimated contract value $700,000, due March 13, 2026, with a 5 percent SLBE bid discount); the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products across multiple jurisdictions (due March 26, 2026). Given the disconnect between the code name and the solicitations tagged to it, the code shows little relevant recent activity for immunosuppressant procurement specifically.